Colorectal Cancer

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
  • Disease/Condition: Rectum
  • Principal Investigator: Jeremy Kortmansky
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
  • Disease/Condition: Colon | Kidney | Melanoma, skin | Other Urinary | Ovary | Breast
  • Principal Investigator: Michael Hurwitz
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
  • Disease/Condition: Colon | Rectum
  • Principal Investigator: Jeremy Kortmansky
An Open-Label Exploratory Phase 2/3 Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer
  • Disease/Condition: Colon | Rectum
  • Principal Investigator: Jeremy Kortmansky
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
  • Disease/Condition: Rectum
  • Principal Investigator: Jeremy Kortmansky
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Selected Solid Tumors
  • Disease/Condition: Colon | Other Skin | Pancreas | Rectum
  • Principal Investigator: Jill Lacy
A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) Plus Binimetinib Alone or the Combination of Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Participants With Metastatic Colorectal Cancer (KEYNOTE-651)
  • Disease/Condition: Colon | Rectum
  • Principal Investigator: Jeremy Kortmansky
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • Disease/Condition: Anus | Bladder | Colon | Esophagus | Kidney | Lip, Oral Cavity and Pharynx | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Unknown Sites | Breast
  • Principal Investigator: Hari Deshpande
An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Myeloid and Monocytic Leukemia | Non-Hodgkin's Lymphoma | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Phase I
  • Principal Investigator: Patricia LoRusso
Medication Adherence in Patients Treated with Capecitabine
  • Disease/Condition: Colon | Breast
  • Principal Investigator: Sarah Mougalian